Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease
progression in some patients, leading to progression-free survival (PFS) and overall survival …

Background. Cardiotoxicity is a serious side effect of drugs used to treat cancer patients.
Older chemotherapy drugs such as the anthracyclins and new targeted therapies, mainly …

Background: Little is known on factors predicting sunitinib toxicity. Recently, the condition of
low muscle mass, named sarcopenia, was identified as a significant predictor of toxicity in …

Cardiovascular disease (CVD) and cancer are the leading causes of death worldwide. With
an increasing number of the elderly population, and early cancer screening and treatment …

Purpose To identify genetic markers in the pharmacokinetic and pharmacodynamic
pathways of sunitinib that predispose for development of toxicities: thrombocytopenia …

Purpose: The objective of this study was to identify genetic polymorphisms related to the
pharmacokinetics and pharmacodynamics of sunitinib that are associated with a prolonged …

Purpose To assess the efficacy and toxicity of sunitinib monotherapy in palliative squamous
cell carcinoma of the head and neck (SCCHN). Patients and Methods Thirty-eight patients …

Therapy for metastatic renal cell carcinoma should be tailored to the circumstances and
preferences of the individual patient. Age should not be a barrier to effective treatment …

Background: Because sunitinib can induce extensive necrosis in metastatic renal cell cancer
(mRCC), we examined whether criteria defined by Choi might be valuable to predict early …

Background A retrospective, registry-based analysis to assess the outcomes of metastatic
renal cell cancer (mRCC) patients treated with sunitinib and sorafenib who developed …